Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment
Regulatory Approval: Kiora Pharmaceuticals has received approval to start a mid-stage trial for KIO-301 aimed at restoring vision in patients with retinitis pigmentosa, a genetic disorder leading to vision loss.
Trial Details: The ABACUS-2 trial will involve 36 patients and is designed as a multi-center, double-masked, randomized, controlled study focusing on individuals with ultra-low vision or no light perception.
Trade with 70% Backtested Accuracy
Analyst Views on KPRX
About KPRX
About the author
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
